Skip to main content
Midas Edge

Equillium Inc

For the period ended Sep 30, 2024. Filed Nov 13, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 13, 2024

EQ$1.46-3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders' Equity

(In thousands, except share data)

Additional · AccumulatedOther · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders'
Shares · Amount · Capital · Income · Deficit · Equity
Balance at December 31, 202234,414,149$3$204,268$76$(172,405)$31,942
Stock-based compensation expense--1,038--1,038
Other comprehensive income---229-229
Net loss----(3,940)(3,940)
Balance at March 31, 202334,414,149$3$205,306$305$(176,345)$29,269
Issuance of common stock under employee stock purchase plan154,351-86--86
Stock-based compensation expense--934--934
Other comprehensive income---35-35
Net loss----(3,343)(3,343)
Balance at June 30, 202334,568,500$3$206,326$340$(179,688)$26,981
Issuance of common stock for Bioniz acquisition849,133-----
Common stock repurchased(298,385)-(260)-(260)
Stock-based compensation expense--979--979
Other comprehensive income---118-118
Net loss----(3,710)(3,710)
Balance at September 30, 202335,119,248$3$207,045$458$(183,398)$24,108
Additional · AccumulatedOther · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders'
Shares · Amount · Capital · (Loss) Income · Deficit · Equity
Balance at December 31, 202335,254,752$3$208,170$140$(185,740)$22,573
Stock-based compensation expense--972--972
Other comprehensive income---283-283
Net loss----(2,734)(2,734)
Balance at March 31, 202435,254,752$3$209,142$423$(188,474)$21,094
Issuance of common stock under employee stock purchase plan169,636-91--91
Stock-based compensation expense--952--952
Other comprehensive loss---(172)-(172)
Net income----468468
Balance at June 30, 202435,424,388$3$210,185$251$(188,006)$22,433
Stock-based compensation expense--1,005--1,005
Other comprehensive loss---(254)-(254)
Net loss----(7)(7)
Balance at September 30, 202435,424,388$3$211,190$(3)$(188,013)$23,177
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.